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Abstract The use of biologics in the treatment of musculo-
skeletal disease has become increasingly more common as
research studies continue to provide further elucidation of
their mechanisms in healing. Platelet-rich plasma, patches,
growth factors, and stem cells are among the many biologics
under active investigation and have varying levels of success
in augmenting surgical or nonoperative interventions.
However, the limitations of these treatments exist, and clear
guidelines for their indications and application have yet to be
established. Well-designed clinical trials will help determine
the appropriate future use of biologics to ensure consistent
outcomes.
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Introduction
Historically, the biologic milieu of healing tissue has been
notoriously difficult to control and improve. However, emerg-
ing research is offering new insights and strategies to provide
multimodal therapy in combating injury to tendons, cartilage,
ligaments, muscles, and bones. Although much work is still in
preclinical stages, these biologics could potentially have an
enormous impact on the field.
The term biologics refers to natural products that are har-
vested to augment the biology of healing. The three main
categories of therapy provided by these products are growth
factor (e.g., platelet-rich plasma), cell (e.g., stem cells), and
tissue (e.g., patches) [1]. Innovations in surgical instrumenta-
tion and repair constructs have helped to decrease the rate of
mechanical failure at the healing site. Yet, surgery still has
shortcomings in many conditions. It is the hope that these
biologics can either augment operative interventions or pro-
vide successful nonoperative treatment. Despite the rapid evo-
lution of biologic therapies, the lack of well-designed clinical
trials limits their human use at this time.
Platelet-rich plasma (PRP)
PRP is a sample of autologous plasma twice centrifuged to
contain a platelet count above baseline. PRP is beneficial in
bone and soft tissue healing for its high concentration of growth
factors and cytokines that stimulate cell proliferation and extra-
cellular matrix protein production [1]. Cytokines such as
platelet-derived growth factor (PDGF)-β, transforming growth
factor (TGF)-β, bone morphogenetic proteins (BMPs), IGF-1,
vascular endothelial growth factor (VEGF), and fibroblast
growth factor (FGF) play documented roles in the healing pro-
cess and may increase the body’s ability to heal a tendon repair
via the normal tendon enthesis, as opposed to scar tissue.
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Concentrating platelets harnesses the abovementioned cy-
tokines and growth factors critical to the healing tissue.
However, the concentration of cytokines and growth factors
released fluctuates and depends upon the platelet recovery
method, amount of whole blood used, platelet activation, final
volume of platelets, and other variables. In an effort to stan-
dardize PRP formulations, classification systems have been
proposed by DeLong et al. [2] and Mishra et al. [3] in which
grades are based on platelet count, activation method, and
WBC count. In a study evaluating respective compositions
of PRP solutions prepared by three commercially available
separation systems (the Cascade, GPS III, and Magellan sys-
tems), Castillo et al. [4•] found that the PRP solutions prepared
by the GPS III and Magellan systems were leukocyte rich,
including high concentrations of WBC, PDGF-αβ,
PDGF-ββ, and VEGF by comparison with the leukocyte-
poor PRP preparations from the cascade system.
Giusti et al. [5] have proposed 1.5×106 platelets per micro-
liter as the optimal platelet concentration for tissue healing and
reported a saturation effect, involving an inhibitory cascade
once a high concentration is reached [6]. Such work, along
with a growing bank of clinical research, marks important
steps toward a better understanding of the therapeutic use of
PRP in orthopedics.
Rotator cuff
The tears of the rotator cuff are common among athletes and
non-athletes alike, and degenerative tears are becoming more
common in the USA as the population ages. If surgery is
indicated, recovery time is largely dependent on the ability
of the tendon to heal the bone. The use of biologic therapy
to speed and improve this process is an attractive prospect.
Multiple investigators have evaluated the effect of rotator
cuff augmentation with PRP, but results have not been univer-
sally positive. In a randomized study of 88 patients with and
without a PRP matrix globule, Castricini et al. [7] found no
difference in constant scores at a mean follow-up of
20 months. Similarly, Jo et al. [8] randomly assigned 48 rota-
tor cuff tear patients with large to massive rotator cuff tears to
PRP-augmented arthroscopic repair or conventional arthro-
scopic repair. They found that PRP application significantly
improved retear rate (20.0 versus 55.6 %) and change in cross
sectional area of the supraspinatus compared to those without
PRP. However, with the exception of overall shoulder func-
tion, clinical outcomes did not differ between the two groups.
In contrast, results from a cohort study by Bergeson et al. [9]
showed that patients who underwent arthroscopic rotator cuff
repair with PRP matrix had a significantly higher retear rate
(56 %) compared with controls (38 %). Moreover, postopera-
tive functional scores were not significantly improved com-
pared with controls. Also, in a randomized controlled trial by
Rodeo et al. [10•] in which 40 patients received PRP-
augmented repair and 39 patients received conventional re-
pair, there were no differences in healing between groups,
outcome scores, strength, and vascularity. Interestingly, PRP
use was a significant predictor of tendon defect at 12 weeks.
These inconsistent results underscore the need to standardize
the indications and use of PRP in rotator cuff repair through
well-designed studies. The possible areas of investigation in-
clude identifying the optimal type of PRP, the timing and
number of injections, and the effect of cytokines or other plas-
ma proteins on PRP.
Ulnar collateral ligament
Injuries to the ulnar collateral ligament (UCL) are common,
particularly in overhead athletes. While surgery has provided
reliably good outcomes, recuperative time can easily last
12 months. Furthermore, some partial tears may not require
reconstruction. To that end, if biologics could be used to en-
hance the healing of the native ligament, thereby obviating
surgery and its associated recovery time, many athletes would
benefit.
Podesta et al. [11] studied the use of PRP injection as an
alternative to surgical reconstruction in treating a cohort of 34
athletes with partial tears of the UCL. At an average follow-up
of 70 weeks, 30 of the 34 athletes had returned to play, aver-
aging a 12-week (range of 10–15 weeks) period before return.
Statistically significant improvements were noted in function-
al outcome measures as well. Similarly, in an unpublished
report of high-level throwers with UCL injuries by Dines
et al., 73 % of players who had failed a course of conservative
therapy had good to excellent outcomes following PRP injec-
tion at an average follow-up of 11 months.
Lateral elbow tendinosis
Lateral elbow tendinosis, or tennis elbow, is a common over-
use injury. While treatments such as corticosteroids are often
administered to relieve pain, long-term relief and functional
improvement remain difficult to achieve. Surgery is often rec-
ommended for patients suffering for as long as a year. The
treatment of lateral elbow tendinosis with biologics may even-
tually be a promising nonoperative alternative.
Peerbooms et al. [12] completed a double-blind random-
ized controlled trial in which autologous PRPwas shown to be
more effective than corticosteroid injections in reducing pain
and increasing function in patients with chronic epicondylitis.
Patients were examined periodically throughout the first year
following the procedure, and 73 % of patients treated with
PRP had improvement in visual analog scale (VAS) and dis-
abilities of the arm, shoulder, and hand (DASH) scores. By
contrast, 49 and 51 % of the corticosteroid group had im-
provements in VAS and DASH scores, respectively.
Whereas, the corticosteroid group recovered more rapidly
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within the first 8 to 12 weeks before declining, the group
treated with PRP continued to improve throughout the year.
These results were consistent with those of Mishra and
Pavelko [13], whose 2006 study reported the relative success
of PRP treatment versus that with a local anesthetic. In a
longer follow-up study, Gosens et al. [14] observed that the
baseline VAS and DASH scores of both the PRP and steroid
groups significantly improved over time. While the pain and
disability of the corticosteroid group returned to baseline
levels within the 2-year period, those of the PRP group con-
tinued to improve.
Hamstring
Hamstring injuries are especially common in athletes reliant
on their lower extremities for running, jumping, and kicking,
thus leaving them with significant impairment and risk of
reinjury. Conventional treatments, whether surgical or physi-
cal therapy and intramuscular corticosteroid injections, can
lead to protracted recovery time, high reinjury rates, and in-
complete recovery [15]. Biologic therapies would represent
new possibilities for a more rapid and complete recovery from
hamstring injury.
Unfortunately, evidence for proximal hamstring treatment
with PRP is severely lacking. In a small retrospective series of
patients who had failed a course of nonoperative treatment for
proximal hamstring tendinopathy, strain, or partial tear,Wetzel
et al. [16] found that patients injected with PRP experienced
symptom relief and return to sports an average of 4.5 months
posttreatment. However, all athletes in the non-PRP injection
also returned to sports, and pain scores posttreatment were not
statistically different between groups.
In another study, Mejia and Bradley [17] treated NFL
players with PRP injection within 24–48 h of hamstring inju-
ry. They showed an earlier return to play of 3 days for grade 1
injuries and 5 days for grade 2 injuries, with an overall one-
game difference in return to play. Despite this success in a
level IV study, more rigorous investigation is needed to clarify
PRP’s role in hamstring injuries.
Achilles tendon
Chronic Achilles tendinopathy is typically ascribed to the
overuse and the failure of a healing response. Nonoperative
treatment can often fail and leave patients with significant
functional limitations in their daily activities. Therefore, a
successful biologic therapy could have enormous impact on
these patients’ outcomes.
de Vos et al. [18] performed the first randomized control trial
of PRP injections in chronic Achilles tendinopathy. Fifty-four
patients were randomized to either an ultrasound-guided injec-
tion of PRP plus eccentric exercises or a placebo injection plus
eccentric exercises and followed for 6 months. After adjusting
for duration of symptoms, there was no significant difference in
outcome measures (patient satisfaction, return to sports, etc.)
between groups at any time point. The same group reanalyzed
results at 1 year and also used ultrasound to evaluate evidence of
tendon structural reorganization. Results showed that PRP injec-
tion with eccentric exercises did not result in clinical improve-
ment and/or improved structural reorganization at 1 year [19].
Osteoarthritis
The preclinical use of PRP injections at the site of osteoarthri-
tis has shown significant improvement in joint healing, by
targeting both cartilage and meniscal tissues [20].
The clinical applications of PRP in the site of knee osteo-
arthritis (OA) have resulted in pain reduction and improved
clinical scores at up to 12-month follow-ups, though it has not
been proven to be more effective than viscosupplementation
in every case [1, 21–24]. Studies comparing pain reduction
and clinical scores for OA following the use of PRP with that
of hyaluronan have shown the clear benefit of PRP to young
patients with less degeneration. In middle-aged patients with
more substantial degeneration, the improvement was similar
between the use of hyaluronan and PRP [1, 21, 23].
Patches
The mechanical augmentation of tendons has been an area of
great interest. Research has led to the development of natural
and synthetic scaffolds derived from mammalian extracellular
matrix (ECM), synthetic polymers, or a combination thereof.
These materials are hypothesized to share the load of forces
across the tendon repair site, thus decreasing the likelihood of
tendon retear [25]. ECM-derived scaffolds are postulated to
provide a conducive chemical and structural environment for
repair healing and remodeling [26–28]. In contrast, synthetic
scaffolds lack biological factors for repair healing; yet, their
mechanical strength may stabilize the repair construct until
host tissue healing can occur [29].
Since the source species and tissue of ECM scaffolds may
vary widely, there is concern about the in vivo host response.
In a rodent abdominal wall model, it was shown that all ECM
scaffolds elicited an early, intense cellular response [30].
Removing cells and cellular remnants from the ECM is
thought to be crucial for a favorable host response. Overall,
the host response is most likely dependent on the species of
origin, tissue of origin, processing methods, methods of ter-
minal sterilization, and mechanical loading environment [31].
The clinical use of scaffolds in humans have raised concern
in some instances [32–36]. The American Academy of
Orthopedic Surgeons currently does not recommend the use
of the non-cross-linked porcine small intestinal submucosa
Restore™ for the treatment of rotator cuff tears in humans
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because of a severe, sterile postoperative inflammatory reac-
tion documented in 20 to 30 % of patients [37, 38]. Better and
safer clinical outcomes, however, have been reported in other
studies using other synthetic scaffolds such as GraftJacket
[39].
Achilles tendon
In a sheep model, Sarrafian and colleagues [40] evaluated a
cross-linked acellular porcine dermal patch and a platelet-rich
plasma fibrin matrix in the acute repair of Achilles tendons.
Surgically transected tendons were reapproximated with su-
tures in groups 1 and 2, whereas a gap was left in group 3. The
patch was used to augment the repair in group 2, and the PRP
matrix was used to fill the gap in group 3, and the gap was also
reinforced with a patch. At 24 weeks, all surgically treated
tendons appeared healed without apparent fibrosis under light
microscopy. However, in group 1 (suture repair only), healing
occurred by increasing tendon thickness and disorganized ten-
don fibers. The other two patch-augmented groups did not
exhibit this degree of tendon thickness or disorganization.
Additionally, the insertion of PRP fibrin matrix within the
gap in group 3 appeared to have aided in the complete bridg-
ing of the gap in all specimens.
Achilles repair augmentation appears to create a biome-
chanically strong construct, according to an analysis by
Magnussen et al. [41]. In this study, tendons from fresh-
frozen human cadavers were sharply tenotomized and
repaired with suture plus ECM xenograft or with suture alone.
The tendons were then subjected to 1000 loading cycles to
86 N and repair site gapping recorded, followed by distraction
to failure. Results showed significantly less gapping in the
augmented tendon group as well as higher load to failure.
Despite the success of patches in animal studies, further inves-
tigation is warranted to determine the indications and out-
comes in humans.
Cytokines
Research has shown that growth factors and cytokines can be
manipulated to enhance the healing process. PDGF-β has
been found to promote fibroblast chemotaxis and proliferative
activity, macrophage activation, extracellular matrix produc-
tion, angiogenesis, and collagen synthesis [42]. It has also
been demonstrated that PDGF-β enhances the proliferation
of bone cells, which can improve the biochemical, mechani-
cal, and structural properties of the healing site [43].
TGF-β can enhance the proliferative activity of fibroblasts
and stimulate the synthesis of type I collagen and fibronectin.
TGF-β is found not only during normal fetal tendon develop-
ment but also in the differentiation of scar tissue during
tendon-to-bone healing. The type of healing that occurs de-
pends on the ratio of different isoforms expressed, with
TGF-β1 associated with scar-mediated healing and TGF-β3
associated with tissue regeneration and “scarless” healing
[44].
Bone morphogenetic proteins (BMPs) are cytokines nor-
mally expressed during embryonic development, which par-
ticipate in fibrocartilage tendon formation via a series of phys-
iologically orchestrated signals. Recombinant human BMP
(rhBMP)-12, rhBMP-13, and rhBMP-14 are expressed at the
tendon interface during embryonic development and are pri-
marily involved in the formation of fibrocartilage and tendon.
Lastly, FGF, expressed by fibroblasts and inflammatory
cells, is involved in the promotion of cellular migration and
angiogenesis to aid in proliferation and remodeling at the site
of tendon repair [45].
Rotator cuff
Preclinical work on the use of growth factors to enhance ro-
tator cuff tendon healing has promising results. Rodeo et al.
[10•] used a mixture of osteoinductive growth factors (BMP-2
to BMP-7, FGF, TGF-β) in a sheep rotator cuff repair model.
Biomechanical testing showed a stronger repair and increased
bone and soft tissue formation at the repair site. Seeherman
et al. [46] delivered rhBMP-12 via a type I/III collagen sponge
to sheep rotator cuff repair. Results showed a significantly
greater load to failure and stiffness compared to controls. In
a rat model of rotator cuff repair augmented with FGF-2, Ide
et al. [47] showed improved biomechanical and histologic
outcomes at 2 weeks. However, there were no differences
between experimental and control groups at 4 or 6 weeks.
Uggen et al. [48] transduced rat tendon fibroblasts with
PDGF and found increased DNA and collagen synthesis in
transduced fibroblasts. A sheep rotator cuff repair model with
PDGF-BB + type I collagen matrix by Hee et al. [49] revealed
an increase in ultimate load to failure in two middle dosages of
PDGF. However, the highest dose group of PDGF had inferior
results indicating a potential negative feedback loop and the
need to elucidate an ideal concentration.
Achilles tendon
A study by Cummings et al. [50] coated Vicryl sutures with
varying concentrations of human platelet-derived growth
factor-BB to evaluate its augmentation effect on suture repair
of Achilles tendon ruptures. Four weeks following repair, they
found a significant increase in the tensile strength of the two
highest dose groups. There was also a trend toward improved
collagen organization in the treated group compared to
controls.
In a rat Achilles tendinopathy model, Solchaga and col-
leagues [51] compared the effect of intra-tendon delivery of
recombinant human platelet-derived growth factor-BB
(rhPDGF-BB), PRP, and corticosteroids versus saline. Two
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different amounts of rhPDGF-BB were administered (3 and
10 μg), and outcomes were assessed at 7 and 21 days after
treatment. Relative to saline, cell proliferation increased 65 %
in the 10 μg rhPDGF-BB. At 7 days, maximum load to failure
was increased in the 3 μg group relative to saline, PRP, and
steroids. At 21 days, maximum load to rupture was increased
in the 10 μg compared to saline, PRP, and steroids and in the
3 μg group compared to saline and steroids. Lastly, stiffness
was increased in the 10 μg relative to the other non-rhPDGF-
BB groups.
Stem cell therapy
Stem cells are undifferentiated, unspecialized cells that have
the potential to be expanded and differentiated into various cell
types in the body. Once implanted, stem cells may function by
direct participation in the repair process, a paracrine effect by
stimulating other local (or distant) host cells, or an anti-inflam-
matory/immunomodulatory role. Studies have indicated poten-
tial for stem cell-based approaches to improve tendon healing,
tendon-to-bone healing, tendon-to-tendon healing, and muscle
regeneration and possibly reversal of fatty infiltration andmus-
cle atrophy. Ni et al. [52] created a rat patellar tendon window
defect model and delivered tendon-derived stem cells in a
fibrin glue carrier. The tendon-derived stem cells significantly
enhanced tendon healing as evidenced by increased collagen
fiber alignment and a significantly higher ultimate stress and
Young’s modulus. Nixon et al. [53] isolated stem cells from
adipose tissue and induced tendonitis in eight horses. Forty-
two days after injection of the stem cells, there was a reduced
inflammatory cell infiltrate, significant improvement in tendon
fiber architecture and organization.
Based on animal studies, isolated stem cells may not be
sufficient for healing. In a rat rotator cuff model in which
animals received bone marrow-derived mesenchymal stem
cells in a fibrin carrier, Gulotta et al. [54] showed there was
no difference in fibrocartilage formation, collagen fiber orga-
nization, and biomechanical strength of the repairs, peak stress
to failure, or stiffness. They concluded that the repair site may
lack the cellular and/or molecular signals necessary to induce
appropriate differentiation of transplanted cells. In another
study, this group modified mesenchymal stem cells with
Membrane type 1 matrix metalloproteinase, a gene upregulat-
ed during embryogenesis in areas that develop into tendon-
bone insertion sites. At 4 weeks, the modified stem cells had
significantly more fibrocartilage, higher ultimate load to fail-
ure, higher ultimate stress to failure, and higher stiffness
values compared with the unmodified stem cells [55]. A sub-
sequent study by Gulotta et al. transduced stem cells with
scleraxis, a transcription factor that is thought to direct tendon
development during embryogenesis. Results at 4 weeks were
similar to the previous study, and the authors concluded mes-
enchymal stem cells genetically modified with scleraxis can
augment rotator cuff healing at early time points [56].
Scaffolds may also provide additional enhancement of cell-
based approaches. In a rabbit model, Yokoya et al. [57] recon-
structed a surgically created defect in the infraspinatus tendon
with a polyglycolic acid (PGA) sheet seededwithmesenchymal
stem cells (MSCs) or PGA alone. Their findings showed that
theMSC group hadmore consistent restoration of fibrocartilage
and Sharpey’s fibers, improved type I to type III collagen ratio,
and better tensile strength than PGA alone or control groups.
Unlike stem cells, the addition of PRP to patches does not
appear to confer significant additive healing effect according
to a recent study. In their rabbit model, Chung et al. [58] dem-
onstrated that the local administration of PRP on repaired
supraspinatus tendon enhanced biological tendon-to-bone
healing and increased the load to failure of the repaired rotator
cuff; however, porcine dermal collagen graft augmentation did
not improve the biological and mechanical properties.
Research has also focused on developing other methods of
manipulating cells to create successful new therapies. Cell
culture modification and slow cytometry sorting can both im-
prove these approaches. Determining the optimal timing, con-
centration, and combination of different growth factors with
stem cells would produce useful clinical information [59–61].
Stem cell therapy in osteoarthritis has been investigated by
numerous groups. A meta-analysis by Wolfstadt et al. noted
that using intra-articular injections of MSCs have proven to
improve pain and function scores in knee OA but that there is
yet little evidence showing any disease-modifying effect [62].
Furthermore, while intra-articular injection is common, sever-
al other methods of delivery and formulation—including scaf-
fold media, encapsulations, combination with factors, and
injecting bone marrow concentrate—are untested and may
be more effective.
Summary
Biologics have been shown to be beneficial adjuvants in the
treatment of tendon, ligament, and cartilage injury. New in-
sights into the healing process have uncovered an important
role for novel therapeutic strategies that use these natural prod-
ucts. However, before biologics become routine tools in the
surgeon’s armamentarium, further research is necessary to
overcome the current limitations.
The work of Castillo et al. [4•] demonstrates that commer-
cially available PRP separation systems produce differing
types of platelet-rich concentrates and WBC concentration,
and these differences have unknown clinical implications.
Therefore, caution is warranted when comparing studies uti-
lizing various commercial systems. Additionally, clinicians
may choose PRP compositions that are either leukocyte rich
or leukocyte poor, but no studies directly investigating the
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ideal composition currently exist. It is becoming more evident
that leukocyte concentration may significantly affect the
healing process. In an animal study, McCarrel et al. [63] found
that a high absolute WBC concentration in PRP contributes to
the expression of inflammatory cytokines. Their results sug-
gest that leukocyte-reduced PRP formulations may possess
the best potential to stimulate superior healing without scar
tissue formation. Conversely, other investigators have demon-
strated detrimental effects of leukocyte-rich PRP. In a study by
Braun et al. [64], synovial cells treated with leukocyte-rich
PRP resulted in significant cell death and proinflammatory
mediator production.
Conclusion
Despite its increasing clinical use, the indications for and ex-
pected outcomes of PRP and other biologics need more clar-
ification. Ideally, well-designed high-quality randomized con-
trolled clinical trials would produce adequate data to give
physicians accurate guidelines in treating appropriately select-
ed patients. Yet, until consensus is reached on the optimal
preparation, concentration, and cytology of PRP, conclusions
from studies will continue to lack full merit and generalizabil-
ity. With proper guidelines and formulations, biologics may
have the potential to revolutionize the approach to treating
many orthopedic ailments. The community eagerly awaits ev-
idence of their safety and efficacy to improve patient
outcomes.
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